Indications for: NEPHROSCAN
As an aid in the scintigraphic evaluation of renal parenchymal disorders.
See full labeling. Give by IV inj (bolus). Administer 74–222MBq (2–6mCi). Begin image acquisition 1–4hrs post-inj. Severely reduced eGFR: delay image acquisition up to 6–24hrs.
See full labeling. Give by IV inj (bolus). Base dose on body wt. Administer 1.85MBq/kg (0.05mCi/kg) with a range of 19–74MBq (0.5–2mCi). Begin image acquisition 1–4hrs post-inj. Severely reduced eGFR: delay image acquisition up to 6–24hrs.
Risk of radiation exposure. Should only be used by trained and experienced physicians in the safe use and handling of radionuclides to minimize radiation exposure. Have resuscitation equipment/medications readily available. Ensure adequate hydration; encourage frequent voiding post-administration. Advanced renal failure: may have an effect on image interpretation. Elderly. Pregnancy. Nursing mothers: interrupt and pump/discard breastmilk for at least 24hrs after administration.
Radioactive diagnostic agent.
Urticaria, rash, pruritus, erythema, syncope, fever, nausea; hypersensitivity reactions.
Generic Drug Availability:
Kit—1 (5 single-dose vials)